Endothelial FAK is required for tumour angiogenesis

Bernardo Tavora, Silvia Batista, Louise E. Reynolds, Shalini Jadeja, Stephen D. Robinson, Vassiliki Kostourou, Ian Hart, Marcus Fruttiger, Maddy Parsons, Kairbaan M. Hodivala-Dilke

Research output: Contribution to journalArticlepeer-review

97 Citations (Scopus)

Abstract

Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that plays a fundamental role in integrin and growth factor mediated signalling and is an important player in cell migration and proliferation, processes vital for angiogenesis. However, the role of FAK in adult pathological angiogenesis is unknown. We have generated endothelial-specific tamoxifen-inducible FAK knockout mice by crossing FAK-floxed (FAKfl/fl) mice with the platelet derived growth factor b (Pdgfb)-iCreER mice. Tamoxifen-treatment of Pdgfb-iCreER;FAKfl/fl mice results in FAK deletion in adult endothelial cells (ECs) without any adverse effects. Importantly however, endothelial FAK-deletion in adult mice inhibited tumour growth and reduced tumour angiogenesis. Furthermore, in in vivo angiogenic assays FAK deletion impairs vascular endothelial growth factor (VEGF)-induced neovascularization. In addition, in vitro deletion of FAK in ECs resulted in reduced VEGF-stimulated Akt phosphorylation and correlating reduced cellular proliferation as well as increased cell death. Our data suggest that FAK is required for adult pathological angiogenesis and validates FAK as a possible target for anti-angiogenic therapies.
Original languageEnglish
Pages (from-to)516-528
Number of pages13
JournalEMBO Molecular Medicine
Volume2
Issue number12
DOIs
Publication statusPublished - Dec 2010

Cite this